Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy

Hematological Oncology

Volumn 30, Issue 4, 2012, Pages 194-199

  Gobbi, Paolo G ^a   Bassi, Emilio ^a   Bergonzi, Manuela ^a   Merli, Francesco ^b   Coriani, Chiara ^b   Iannitto, Emilio ^c   Luminari, Stefano ^d   Polimeno, Giuseppe ^e   Federico, Massimo ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c Ospedale SS Annunziata   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e MIULLI GENERAL HOSPITAL   (Italy)

Author keywords

Chemotherapy; Clinical response; Early relapse; Radiotherapy; Tumour burden

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG TREATMENT FAILURE; FEMALE; HODGKIN DISEASE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RELATIVE TUMOR BURDEN; SCORING SYSTEM;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMORADIOTHERAPY; DACARBAZINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; ITALY; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION TOLERANCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TUMOR BURDEN; VINBLASTINE;

EID: 84870942655     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1024     Document Type: Article

References (19)

1. Specht L. Tumor burden as the main indicator of prognosis in Hodgkin's disease. Eur J Cancer 1992; 28: 1982-1985.
2. Gobbi PG, Ghirardelli ML, Solcia M, et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol 2001; 19: 1388-1394.
3. Gobbi PG, Broglia C, Di Giulio G, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 2004; 101: 1824-1834.
4. Josting A. Prognostic factors in Hodgkin lymphoma. Exp Rev Hematol 2010; 3: 583-592.
5. Gobbi PG, Valentino F, Bassi E, et al. Chemoresistance as a function of the pre-therapy tumor burden and the chemotherapy regimen administered. Clin Lymphoma Myeloma Leuk 2011; 11: 396-402.
6. Lister TA, Crowther D, Sutcliff SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. Cotswolds Meeting. J Clin Oncol 1989; 7: 1630-1636.
7. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant criteria. J Clin Oncol 2007; 25: 579-586.
8. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252-259.
9. Iannitto E, Minardi V, Gobbi PG, et al. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lympphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. Clin Lymphoma Myeloma Leuk 2009; 9: 138-144.
10. Gobbi PG, Levis A, Chisesi T, et al. ABVD vs. Stanford V vs. MOPPEBVCAD with optional and limited radiotherapy in advanced-stage Hodgkin's lymphoma. Final results of a multicenter, randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23: 9198-9207.
11. Federico M, Luminari S, Iannitto E, et al. ABVD vs. BEACOPP vs. CEC for the initial treatment of patients with advanced Hodgkin lymphoma. Results from the HD2000 GISL trial. J Clin Oncol 2009; 27: 805-811.
12. Wickramasinghe SN. Human Bone Marrow. Blackwell Scientific Publications: Oxford, GB, 1976; 211-216.
13. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 16: 274-280.
14. Armitage P, Berry G. Statistical Methods in Medical Research (2nd edn edn). Blackwell Scientific Publication: Oxford, GB, 1987; 396-369.
15. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of breast cancer. J Clin Oncol 1984; 2: 1281-1288.
16. Tannock IF. Tumor physiology and drug resistance. Cancer Metast Rev 2001; 20: 123-132.
17. Uematsu T, Kasami M, Yuen S. Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy. Eur Radiol 2010; 20: 2315-2322.
18. Fisher RI, DeVita VT, Hubbard SP, et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Int Med 1979; 90: 761-763.
19. Longo D, Duffey P, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.